Boron for Osteoporosis
Boron has not been shown to prevent or treat osteoporosis. A handful of small, short studies hint at effects on calcium handling and hormones, but no trial has measured whether boron actually protects bone density or reduces fractures.
Why this grade7-layer evidence engine
The human evidence is thin and indirect. The most-cited study (PMID 3678698, n=12 postmenopausal women) found that 3 mg/day of boron lowered urinary calcium and magnesium loss and raised estrogen and testosterone, but it measured these surrogate markers rather than bone, so its 'prevents demineralization' claim is an inference, not a result. A small 1-year trial in female athletes (PMID 7889886, n=28) saw only minor bone-density shifts that tracked physical activity, not boron, and a 1-week study in 8 healthy men (PMID 21129941) looked at hormones, not bone.
Crucially, no large randomized trial and no fracture or bone-density endpoint exists in osteoporosis patients. The two main syntheses (PMID 26770156 and PMID 32540741) are narrative reviews leaning on the same older, small studies, with no meta-analysis or formal GRADE rating; one appeared in a complementary-medicine journal.
Authorities echo this caution. EFSA concluded a cause-and-effect link between boron and normal bone has not been established, the US FDA sets no Daily Value for boron, and the Cleveland Clinic states there is not enough research to suggest a benefit. Major osteoporosis bodies do not recommend boron, supporting the Weak (C) grade.
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditable▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.445
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status